AI‑driven digital biomarkers promise to transform patient monitoring, early disease detection, and therapeutic decision‑making. However, turning a...
data governance
Designing and validating cardiovascular digital biomarkers for clinical trials is no longer a niche endeavor—it’s a strategic...
When the FDA opens a new portal for real‑world evidence (RWE) submissions, companies must adapt quickly. A...
In 2026, real‑world evidence (RWE) has become a cornerstone of FDA decision‑making. Researchers and sponsors must now...
In 2026, pharmaceutical companies and regulators alike are turning to blockchain‑enhanced real‑world evidence (RWE) registries to meet...
In 2026 the promise of data‑driven care has moved beyond buzzword to routine clinical practice. For chronic...
How to Launch a Real‑World Evidence Registry for Oncology Drugs: A Step‑by‑Step Guide Launching a Real‑World Evidence...
Zero-Knowledge Proofs Empower Patient Data Control: A Revolutionary Framework for Secure Medical Data Sharing Zero-Knowledge Proofs (ZKPs)...
Integrating SaMD as Primary Outcome Measures in Decentralized Clinical Trials: A Practical Framework
The shift to decentralized clinical trials (DCTs) creates a unique opportunity to use software as a medical...